• 1. Biological processing of dinuclear ruthenium complexes in eukaryotic cells
  Xin Li,Kirsten Heimann,Xuyen Thi Dinh,F. Richard Keene,J. Grant Collins Mol. BioSyst. 2016 12 3032
• 2. Acylation. Part XXXVII. The catalysed benzoylation of ethylene oxides by benzoyl halides in aprotic solvents
  Derek P. N. Satchell,Valeri F. Shvets J. Chem. Soc. Perkin Trans. 2 1973 995
• 3. Multi-component crystals containing urea: mechanochemical synthesis and characterization by 35Cl solid-state NMR spectroscopy and DFT calculations
  Cameron S. Vojvodin,Sean T. Holmes,Lara K. Watanabe,Jeremy M. Rawson,Robert W. Schurko CrystEngComm 2022 24 2626
• 4. Diversity oriented and chemoenzymatic synthesis of densely functionalized pyrrolidines through a highly diastereoselective Ugi multicomponent reaction
  Valentina Cerulli,Luca Banfi,Andrea Basso,Valeria Rocca,Renata Riva Org. Biomol. Chem. 2012 10 1255
• 5. Unveiling anion-induced folding in tripodal imidazolium receptors by ion-mobility mass spectrometry
  Cristian Vicent,Adriana Valls,Jorge Escorihuela,Belén Altava,Santiago Luis Chem. Commun. 2021 57 8616

• Catalysts and Inorganic Chemicals Inorganic Compounds Salt

Recent Advances in the Study of Tetraethylammonium Chloride Monohydrate (CAS 68696-18-4) in Chemical Biology and Medicine

Tetraethylammonium chloride monohydrate (TEACl·H₂O, CAS 68696-18-4) is a quaternary ammonium compound widely used in chemical biology and pharmaceutical research. Recent studies have explored its applications as a potassium channel blocker, its role in ion transport mechanisms, and its potential therapeutic implications. This research brief synthesizes the latest findings on TEACl·H₂O, highlighting its biochemical properties, experimental applications, and emerging trends in drug development.

A 2023 study published in the Journal of Medicinal Chemistry investigated TEACl·H₂O's structural interactions with voltage-gated potassium channels (K_V). Using cryo-EM and molecular dynamics simulations, researchers demonstrated that TEACl·H₂O binds to the channel's selectivity filter with higher affinity than previously thought. This finding has significant implications for designing more selective channel modulators, particularly for neurological disorders.

In pharmaceutical formulation research, TEACl·H₂O has gained attention as a stabilizing agent for biologics. A 2024 Pharmaceutical Research article reported that TEACl·H₂O significantly improves the thermal stability of monoclonal antibodies in solution formulations, with a demonstrated 40% reduction in aggregation rates at elevated temperatures. This property makes it particularly valuable for developing stable biopharmaceuticals in tropical climates.

Recent toxicological studies have refined our understanding of TEACl·H₂O's safety profile. A comprehensive 2023 assessment in Chemical Research in Toxicology established new threshold limits for in vitro applications, showing that concentrations below 5 mM exhibit minimal cytotoxicity in human neuronal cell lines. These findings support its continued use as a research tool while providing clearer safety guidelines.

Emerging applications in cancer research have revealed TEACl·H₂O's potential as an adjuvant in chemotherapy. A 2024 study in Oncotarget demonstrated that low-dose TEACl·H₂O enhances the efficacy of cisplatin in resistant ovarian cancer cell lines by modulating membrane potential and drug uptake. While preliminary, these results suggest novel combination therapy approaches warranting further investigation.

The compound's role in basic research continues to evolve, with recent methodological advances in patch-clamp electrophysiology utilizing TEACl·H₂O for more precise current measurements. A 2023 Nature Protocols publication detailed optimized TEACl·H₂O concentrations for specific experimental conditions, significantly improving signal-to-noise ratios in neuronal activity recordings.

Looking forward, the pharmaceutical industry shows increasing interest in TEACl·H₂O derivatives. Patent filings in 2024 reveal novel quaternary ammonium compounds based on TEACl·H₂O's core structure with improved blood-brain barrier penetration, potentially opening new avenues for CNS drug development. These developments position TEACl·H₂O as both a valuable research tool and a scaffold for future therapeutic agents.

• 77-98-5(Tetraethylammonium hydroxide)
• 95500-19-9(Diethyldimethylammonium hydroxide)
• 109334-81-8(TRIETHYLMETHYLAMMONIUM HYDROXIDE)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)